Yi-Bin Chen, MD, provides insight on treatment of steroid-refractory chronic GVHD with ruxolitinib.
March 28th 2022
Yi-Bin Chen, MD, discusses the work-up, diagnosis, and treatment of a 42-year-old woman with moderate steroid-refractory chronic graft-versus-host disease (GVHD).
A focused discussion on various risk factors for developing chronic GVHD and steroid-refractory disease.
A comprehensive overview of the symptoms of and organs involved in chronic GVHD.
Insight on early diagnosis of chronic GVHD and the tools clinicians use to assess GVHD severity.
Yi-Bin Chen, MD, discusses available treatment options for patients with steroid-refractory chronic GVHD.
A discussion of data from the REACH3 trial and real-world data on the efficacy of ruxolitinib in patients with steroid-refractory chronic GVHD.
A brief overview of safety and adverse events in the REACH3 trial of ruxolitinib in patients with steroid-refractory chronic GVHD.
Yi-Bin Chen, MD, reflects on the patient case and outlines strategies for educating and managing patients at risk of developing chronic GVHD.
Closing out his discussion, Yi-Bin Chen, MD, talks about unmet needs, ongoing clinical trials, emerging treatment options for patients with steroid-refractory chronic GVHD.